Fortrea Holdings Inc.

Fortrea Holdings Inc. is a contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers globally. Its services include clinical pharmacology offerings such as clinical research units, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics. It also offers clinical development services covering phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. Additionally, Fortrea provides consulting services including product development and regulatory support, market access and health economics, outcomes research, and real-world evidence services.

Fortrea Holdings Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol FTRE. The trading currency for its shares is the US Dollar (USD), as the company is headquartered in the United States and its primary listing is on a US-based exchange. Investors can trade FTRE shares on NasdaqGS during regular market hours, and the stock is denominated in USD, which is typical for US-listed equities.

Fortrea Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a contract research organization, it supports the development of biopharmaceutical products and medical devices, which places it at the intersection of healthcare services and biotechnology. The company's work involves clinical trials, regulatory affairs, and other research services that are critical to bringing new therapies and devices to market. While the industry classification is 'Biotechnology,' Fortrea itself is a service provider rather than a drug developer, focusing on enabling its clients' research and development efforts.

Fortrea Holdings Inc. is headquartered in Durham, North Carolina, United States. The company serves a global customer base, providing its biopharmaceutical and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. Its services span clinical pharmacology, clinical development, and consulting, with operations likely extending across multiple regions to support international clinical trials and regulatory submissions. The company was incorporated in 2023, making it a relatively new entity, though it builds on the experience of its predecessor organizations.

Fortrea Holdings generates revenue by offering a comprehensive range of contract research services to pharmaceutical, biotechnology, and medical device companies. Its revenue model is fee-for-service, where clients pay for specific research and development activities such as clinical trial management, data analysis, regulatory consulting, and pharmacovigilance. The company's clinical pharmacology segment includes services like bioanalytical testing and pharmacokinetic modeling, while its clinical development segment covers phase I-IV studies and real-world evidence. Additionally, consulting services in product development, market access, and health economics contribute to revenue. By partnering with clients throughout the drug and device development lifecycle, Fortrea earns income from project-based contracts and long-term collaborations.